GlassScriptPhysician profile
Syed Ahmed
NPI 1700880697
$36,552.71
in general payments reported to CMS, 2019-2025
90 companies · $6,793 in 2025
The $6,793 reported for 2025 was more than what 77% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,444 · 2020: $3,448 · 2021: $4,350 · 2022: $4,968 · 2023: $6,413 · 2024: $7,136 · 2025: $6,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,642.85 |
| Education | $1,699.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,416.29 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $3,256.21 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $2,017.21 | 2019-2025 | Kisqali, Piqray |
| E.R. Squibb & Sons, L.L.C. | $1,747.20 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $1,711.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,708.67 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $1,382.88 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $1,345.16 | 2019-2025 | |
| Celgene Corporation | $1,271.57 | 2019-2025 | Reblozyl, Opdualag, Breyanzi |
| Astellas Pharma US INC | $1,267.89 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Amgen INC. | $1,168.05 | 2019-2024 | Lumakras, Imdelltra (Amg 757), Nplate |
| Seagen INC. | $1,129.80 | 2019-2025 | Adcetris, Tukysa, Tivdak |
| Genzyme Corporation | $1,074.29 | 2019-2025 | |
| Lilly USA, LLC | $835.58 | 2019-2024 | Jaypirca, Verzenio |
| Genentech USA, INC. | $790.87 | 2019-2025 | Polivy, Venclexta, Alecensa |
Show all 90 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $742.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $661.00 | 2019-2025 | Enhertu, Injectafer |
| Rigel Pharmaceuticals, INC. | $636.59 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Sobi, INC | $634.75 | 2022-2025 | |
| Abbvie INC. | $554.51 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $537.65 | 2020-2025 | Ojjaara, Shingrix, Blenrep |
| Gilead Sciences, INC. | $469.35 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $458.43 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $411.95 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Alnylam Pharmaceuticals INC. | $398.99 | 2023-2025 | Amvuttra, Onpattro, Givlaari |
| Regeneron Healthcare Solutions, INC. | $392.98 | 2019-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $375.43 | 2019-2025 | Onivyde |
| Alexion Pharmaceuticals, INC. | $311.93 | 2019-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $301.02 | 2019-2023 | Imbruvica |
| Myriad Genetic Laboratories, INC. | $277.40 | 2021-2024 | Myrisk |
| Pharmacosmos Therapeutics INC. | $273.60 | 2023-2025 | Monoferric, Cosela |
| Stemline Therapeutics INC. | $272.67 | 2023-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $255.38 | 2020-2025 | Zepzelca |
| Pharmaessentia USA Corporation | $238.92 | 2023-2025 | Besremi |
| Tersera Therapeutics LLC | $235.75 | 2022-2025 | Zoladex |
| Exelixis INC. | $195.72 | 2023-2025 | Cabometyx |
| Beigene USA, INC. | $178.47 | 2020-2023 | Brukinsa |
| Dova Pharmaceuticals | $166.28 | 2020-2021 | |
| Coherus Oncology, INC. | $166.12 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $162.64 | 2020-2025 | Xpovio |
| Taiho Oncology, INC. | $154.79 | 2020-2025 | |
| Puma Biotechnology, INC. | $151.10 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.83 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $139.24 | 2020-2025 | Provenge |
| Foundation Medicine, INC. | $138.74 | 2019-2023 | |
| Morphosys, US INC. | $137.61 | 2021-2023 | Monjuvi |
| Emd Serono, INC. | $133.69 | 2019-2024 | Bavencio |
| Kyowa Kirin, INC. | $128.75 | 2020-2025 | Poteligeo |
| G1 Therapeutics, INC. | $122.68 | 2022-2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $110.97 | 2023-2025 | Fotivda |
| Secura Bio, INC. | $106.85 | 2020-2022 | |
| Kite Pharma, INC. | $101.54 | 2021-2025 | Yescarta |
| Geron Corporation | $99.93 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $96.67 | 2020-2023 | Qinlock |
| Immunogen, INC. | $79.16 | 2023 | Elahere |
| Cti Biopharma Corp. | $79.02 | 2022-2023 | Vonjo |
| Adaptive Biotechnologies Corporation | $72.54 | 2023-2024 | Clonoseq |
| Clovis Oncology, INC. | $69.24 | 2019 | |
| Servier Pharmaceuticals LLC | $68.69 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $67.42 | 2023-2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $62.04 | 2022-2025 | Pyrukynd |
| Ge Healthcare | $60.61 | 2021-2022 | |
| Mirati Therapeutics, INC. | $57.50 | 2023-2024 | Krazati |
| Eusa Pharma (US) LLC | $56.22 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $52.72 | 2024-2025 | Sylvant, Enjaymo |
| Acrotech Biopharma INC. | $49.31 | 2022-2024 | Beleodaq |
| Myovant Sciences INC. | $46.23 | 2021-2022 | |
| Global Blood Therapeutics, INC. | $42.65 | 2020-2022 | |
| Genmab U.S., INC. | $39.26 | 2024-2025 | Epkinly |
| Janssen Pharmaceuticals, INC | $38.00 | 2022 | |
| Novocure INC. | $35.01 | 2025 | Optune Lua (Novottf-200t) |
| Spectrum Pharmaceuticals INC. | $33.68 | 2019-2023 | Rolvedon |
| Acceleron Pharma, INC. | $28.85 | 2021 | |
| Corcept Therapeutics | $28.53 | 2025 | Korlym |
| Tempus Ai, INC | $28.52 | 2024 | Xt Cdx |
| Amag Pharmaceuticals, INC. | $27.50 | 2019-2022 | |
| Blueprint Medicines Corporation | $26.91 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.91 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $19.32 | 2025 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $18.18 | 2022 | |
| Tolmar, INC. | $18.08 | 2023 | |
| Immunocore Limited | $17.83 | 2024 | Kimmtrak |
| Tg Therapeutics, INC. | $17.66 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $16.42 | 2022 | |
| Epizyme, INC. | $16.06 | 2023 | Tazverik |
| Helsinn Therapeutics (U.S.), INC. | $14.39 | 2019 | |
| Iovance Biotherapeutics, INC. | $13.30 | 2025 | Amtagvi |
| Veracyte, INC. | $12.23 | 2024 | |
| Medtronic Vascular, INC. | $11.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $9.67 | 2019 |
Drugs and devices associated with these payments
Keytruda $987Rybrevant $961Tecvayli $759Nubeqa $744Reblozyl $737Imfinzi $623Darzalex $567Enhertu $557Venclexta $455Talvey $412Sarclisa $408Lynparza $369Xtandi $362Jakafi $353Opdivo $347Lenvima $342Kisqali $335Adcetris $335Erleada $331Scemblix $323Ojjaara $320Calquence $289Doptelet $286Jaypirca $281Vitrakvi $279Stivarga $279Orserdu $273Braftovi $272Verzenio $270Monjuvi $263Padcev $257Vonjo $257Elrexfio $252Tukysa $248Rezlidhia $245Tavalisse $245Amvuttra $242Pluvicto $239Besremi $239Libtayo $238Mektovi $232Lorbrena $230Orgovyx $211Zoladex $206Talzenna $201Monoferric $200Myrisk $182Lutathera $177Ibrance $175Trodelvy $174Onivyde $168Fruzaqla $165Fabhalta $162Inlyta $160Ultomiris $159Gavreto $158Zynyz $152Lumakras $148Zepzelca $145Cosela $145Udenyca $131Welireg $129Andexxa $128Imbruvica $124Bosulif $123Piqray $120Opdualag $118Enjaymo $117Polivy $111Fotivda $111Elahere $106Onpattro $103Rytelo $99.93Cabometyx $95.73Tasigna $93.17Alecensa $88.89Tecentriq $88.89Provenge $87.83Yescarta $83.64Epkinly $82.83Inqovi $82.01Lonsurf $82.01Imdelltra (Amg 757) $80.49Comirnaty $78.58Phesgo $75.78Balversa $74.74Xpovio $72.64Clonoseq $72.54Xalkori $71.92Paxlovid $71.52Poteligeo $66.19Promacta $66.12Brukinsa $63.35Tivdak $62.90Ninlaro $58.38Krazati $57.50Akeega $55.05Givlaari $53.55Vyloy $52.99Carvykti $52.25
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.